Eli Lilly (LLY)
$898.10
0.00 (0.00%)
LLY Stock Quote Delayed 30 Minutes
Effective Alzheimer’s Drugs May Be Just Three Years Away
New research, both by scientists and the big drug companies, is leading to increased hope for sufferers of Alzheimer's disease.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
18,356
Day's Range
-
52-Week Range
$434.34 - $918.50
Dividend & Yield
$4.52 (0.50%)
LLY Stock Predictions, Articles, and Eli Lilly News
PowerShares’ High-Dividend ETF: Good Fund, GREAT Sales Pitch
PowerShares' new high-dividend, low-volatility fund SPHD has several attractive selling points and is well-timed to capture the current thirst for yield.
16 Ultimate Dependable Dividend Payers
A Citigroup screen for creditworthy dividend-payers results in a fine list of dependable, high-yielding stocks.
7 Pharmaceutical Stocks to Buy Now
The grades of seven Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
A Healthy Portfolio Is Heavy in Health Care
Investors would be foolish to ignore the massive demographic shift and growth potential that is boosting health care stocks right now.
7 Pharmaceutical Stocks to Buy Now
The grades of seven Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
The 10 Best Buffett Dividend Stocks
Despite paring back on several dividend stocks last quarter, Berkshire hasn't given up on income altogether. Here are its top dividend payers.
Eli Lilly Might Have an Alzheimer’s Cure
Eli Lilly's stock is set to soar Friday morning after a trial for its Alzheimer's drug solanezumab showed promising results for early-stage patients.
Cracked Wood in Market Resistance Zone Spells Trouble
Markets may be getting ahead of themselves at this point, and savvy investors may want to revisit some portfolio names that have run up, including these pharmas
6 Pharmaceutical Stocks to Buy Now
The grades of 6 Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
ETF Alternatives for Last Week’s Hot Stocks
Here are ways to play the financial services, conglomerate, consumer staples and pharmaceutical stocks we wrote about last week.
6 Pharmaceutical Stocks to Buy Now
The grades of six Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
3 Dividend Plays for a Fair Price
Don't dump your money into sparsely yielding Treasuries or money-market accounts. Especially when there's some fairly priced dividend stocks on the shelf.
7 Long-Term Demographic Trends to Play
Earnings and stock fundamentals are important, but don't miss the forest while looking at the trees. Here are the big-picture demographic trends to keep your eye on.
The New Nifty Fifty
Long-term investors may find opportunities in this group of largely household names -- with steady earnings and often above-average dividends.
Merck Could Have a Home Run in Sight
Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.
Medidata Solutions a Strong Buy in Cloud Computing
Medidata Solutions is a fast-growing cloud services provider to the health care industry that is poised for even better growth and is a buying opportunity
ETF Alternatives for Last Week’s Hot Stocks
Here's a look at some ETF alternatives to some of InvestorPlace's expert stock picks from the previous week, including MSFT and BBBY.
